A diagnosis of familial hemophagocytic lymphohistiocytosis (FHL) was established in an 18-month-old boy who presented with prolonged fever of unknown origin, severe pancytopenia, hepatosplenomegaly and hypofibrinogenemia. Serum levels of ferritin and soluble interleukin-2 receptor (SIL2R) were highly elevated, and the number of natural killer (NK) cells was markedly decreased. An allogeneic stem cell donor was neither found in the family nor in unrelated donor registries; however, an umbilical cord blood (UCB) donor request revealed a 5/6 HLA-matched UCB. After conditioning with busulphan 16 mg/kg body weight (BW), cyclophosphamide 120 mg/kg BW and etoposide (VP-16) 900 mg/m 2 the patient received 19.6 × 10 7 UCB nucleated cells/kg BW. White blood count (WBC) reached 1.0 × 10 9 /l on day +45. Chimerism studies showed full and permanent hematopoietic and lymphopoietic engraftment on day +16. However despite full engraftment the patient still experienced two severe relapses of his disease after stem cell transplantation with the highest ferritin level in the range of 10 3967 g/l (n = 7-142). NK cell function appeared only 6 months after UCB transplantation followed by a decrease of FHL markers and resolution of disease activity. This clinical outcome indicates that unless competent immunologic engraftment after transplantation is established, FHL is capable of relapsing even if complete three-lineage engraftment is achieved.
splenomegaly pancytopenia, hypertrigyceridemia, hypofibrinogenemia, and elevated serum levels of ferritin, soluble interleukin-2 receptor (SIL2R), interferon-␥ (IFN-␥) and tumor necrosis factor (TNF). [1] [2] [3] [4] [5] [6] Meningeal involvement is manifested by lymphohistiocytic pleocytosis combined with increased protein levels in the cerebrospinal fluid (CSF). The clinical course of this disease is usually short and fatal. Remissions can be induced with the systemic administration of cyclosporin A (CsA), 7 steroids, etoposide (VP-16) 8, 9 and central nervous system (CNS) prophylaxis, whereas cure can only be achieved by allogeneic bone marrow transplantation (BMT). [10] [11] [12] [13] Although the pathogenesis and etiology of the disease are not clear to date, the clinical occurrence of fatal infections suggests that immunodeficiency might play a prominent role in FHL. Several defects of the immune system in FHL are reported including: defective natural killer (NK) activity against K562 target cells; no effect of interferon-␣ on restoration of NK activity; impaired interleukin-1 production of peripheral blood mononuclear cells (PBMNC), not restored by indomethacin; impaired interferon production; decreased Tlymphocyte response to mitogens, and of antigen-induced lymphocyte proliferation among others. [14] [15] [16] [17] This case report presents the first successful unrelated mismatched umbilical cord blood transplant (UCBT) for this disease.
Case report
An 18-month-old boy was referred to our hospital with the diagnosis of fever, pneumonia and meningitis. He was the first-born child of healthy nonconsanguineous parents. The pre-and perinatal periods had been uneventful. There was no family history of FHL. He was treated with various broad-spectrum antibiotics because he appeared to be septic, though there was no evidence of bacterial, fungal or mycotic contamination of the blood, skin, stool, urine and sputum. Despite aggressive antibiotic therapy, the clinical status of the child worsened and he was transferred to the intensive care unit. On admission he was listless and the skin was pale and icteric, showing petechiae predominantly on the chest and extremities. Cervical and inguinal lymph nodes were enlarged. Heart and respiratory sounds were normal. The liver was palpable 8 cm and the spleen 5 cm below the costal margin. Bone marrow (BM) aspiration at that time revealed normocellularity of granulopoiesis, erythropoiesis and thrombopoiesis with a prominent increase in stroma. Shortly after examination of the BM the patient developed severe pancytopenia with a red blood count (RBC) of 2950 × 10 9 /l and a hemoglobin of 7.8 g/dl. Platelet count was below 20 × 10 9 /l. He had 1.4 × 10 9 /l leukocytes with 4% bands, 47% segmented neutrophils, 13% monocytes, 4% eosinophils and 32% lymphocytes. NK activity was barely detectable below 2.5% with an effector/target ratio of 20:1. Blood chemistry was as follows: protein 6.8 g/dl, albumin 2.4 g/dl, glutamate oxalacetate transaminase (GOT) 34 U/l, glutamate pyruvate transaminase (GPT) 48 U/l, ␥-glutamyl transpeptidase (␥-GT) 256 U/l, lactate dehydrogenase (LDH) 653 U/l, total bilirubin 2.4 mg/dl, direct bilirubin 1.8 mg/dl, C-reactive protein 28 mg/l, triglycerides 492 mg/dl and cholesterol 148 mg/dl. Coagulation tests revealed hypocoagulability with an activated partial thromboplastin time (aPTT) of 106 s, a prothrombin time (PT) of 32%, and a reptilase time of 28 s. Fibrinogen was below 50 mg/dl. Serum immunoglobulin levels including IgG subtypes were normal whereas serum levels of ferritin and SIL2R were highly elevated (70.761 g/l and Ͼ6700 U/ml), respectively. X-ray and computed tomography scan of the chest were normal, ultrasound investigation of the abdomen disclosed hepatosplenomegaly. CSF showed normal cellularity and normal protein content. Splenic aspiration and repeated BM aspirations now revealed a diagnosis of FHL with significant hemophagocytic activity of histiocytes. The patient received VP-16 150 mg/m 2 /day intravenously (i.v.) for 2 days in combination with prednisone 0.5 mg/kg/day i.v. for 68 days as induction therapy. He showed a striking defeverescence on therapy and attained remission which was maintained by continuous administration of i.v. CsA, maintained at serum levels between 150 and 250 ng/ml, and weekly i.v. VP-16. Although disease activity ameliorated clinically, serum chemistry showed further biological activity with elevated serum levels of ferritin and low numbers of NK cells without specific lysis potential (Figure 1) . Therefore, the search for a suitable unrelated stem cell donor was intensified and finally a 5/6 HLA-matched female UCB specimen became available at the UCB Bank in Düsseldorf, Germany /l only on day +45. He remained platelet and red cell transfusion dependent for 2 months. Graft-versus-host disease (GVHD) prophylaxis consisted of CsA (5 mg/kg BW i.v.). Acute grade I GVHD (skin rash) was treated with a 12-day course of i.v. prednisone. Chimerism studies were performed by fluorescent in situ hybridization (FISH) analysis of the Y-chromosome. Periodic FISH investigations revealed complete and permanent hematopoietic and lymphopoietic donor engraftment on day +16. Immunologic reconstitution, however, was slow. The number of T-lymphocytes in the peripheral blood reached 0.1 × 10 9 /l only 2 months after transplantation, B-lymphocytes were first detectable after 4 months, and NK cells 1 month after transplantation, respectively ( Figure 2 ). The post-transplant course was complicated by two relapses of FHL. The first was noticed at day +11 and was characterized by acute enlargement of the liver and spleen, fever without proven infection, a dramatic elevation of serum levels of ferritin (from 1245 g/l up to 103 957 g/l) and SIL2R (from 560 U/ml up to Ͼ5000 U/ml) and a decrease of WBC (from 0.5 to 0.1 × 10 9 /l). Graft rejection was excluded by chimerism analysis which constantly revealed Ͼ99% donor hematopoiesis. A local or systemic infection was excluded by extensive microbiologic investigation. After reaching a second remission of FHL with high doses ) once weekly for 9 consecutive weeks together with continuous i.v. CsA. Lung biopsy was not possible due to the life-threatening character of the respiratory distress. The child finally recovered, and CsA treatment was stopped on day +186 without clinical and serologic recurrence of FHL. Hematopoiesis remained constantly of donor type which was proven by FISH analysis of the peripheral blood (repeated monthly) and two further BM aspirations (at day +163 and +228). The patient was discharged from hospital at day +240 (Figure 3) . Recent check-up 1 year after UCBT revealed clinical and immunologic remission with normal NK cell function, as well as normal ferritin and SIL2R levels.
Discussion
Sustained remission of FHL can be achieved with a combination of etoposide, CsA, steroids and intrathecal methotrexate. 8 However, most of the children treated with conventional regimens eventually relapse. This may be caused by two facts. The first is the presence of disease sanctuary in the CNS. CNS involvement is often present at diagnosis and even more frequent at relapse. The second and most likely explanation of conventional treatment failure is related to the pathophysiology of FHL itself, as the underlying genetic susceptibility to histiocytic activation is poorly accessible to chemotherapy. From the analysis of 22 children treated with standard (induction and maintenance) chemotherapy Blanche et al 9 proposed that the poor longterm outcome of conventional chemotherapy justifies allogeneic matched stem cell transplantation in FHL. The results of HLA-matched sibling transplantation are promising to date, although it seems that the post-transplant course is much more often complicated than is the case for stem cell transplantation for other diseases. 10 In addition, a matched sibling transplant is available in only 30% of all cases. Only limited experience is present using unrelated and mismatched donors. 9, 11, 12 The use of T cell-depleted BM of HLA-nonidentical related donors in combination with anti-adhesion antibodies specific for the ␣-chain of the leukocyte function-associated antigen 1 (CD11a) infused pre-, and post-transplant to prevent graft rejection seems to be a reasonable alternative in the future. 13 The decision to use a 5/6 HLA-matched UCB in the absence of an HLAmatched sibling was based on the clinical advantages of cord blood, the distinctive proliferative potential and the relative immaturity of cord blood lymphocytes in the development of GVHD. 19, 20 However the clinical course of this HLA-mismatched UCBT raises some questions. Despite complete hematopoietic and lymphopoietic engraftment, two severe relapses of FHL occurred. One might speculate that the conditioning regimen was not able to eradicate the histiocytic activity of the disease completely and that reappearance of immunologic competence is probably the main goal of transplantation in FHL. The time to the developing immunologic reconstitution is unpredictable. It depends upon the conditioning regimen, composition of the stem cell source (ie stem cell selection), the underlying disease and other parameters. 21, 22 We were able to demonstrate that with the appearance of both, B-and T-lymphocytes in the peripheral blood together with an increasing number of functioning NK cells, remission of FHL could finally be achieved.
We conclude that transplantation of mismatched UCB in patients with FHL is feasible but, depending on the duration of the immunologic reconstitution, relapses of the disease can occur prompting the need for immediate reinduction with conventional chemotherapy, even after complete hematologic engraftment has been established.
